Tirzepatide

Tirzepatide is a synthetic 39-amino acid dual GIP/GLP-1 receptor co-agonist with a C18 fatty diacid moiety that confers albumin binding and extends the plasma half-life to approximately 5 days — enabling once-weekly dosing. The sequence is based on a native GIP structure modified to incorporate GLP-1 receptor activity across both pathways simultaneously.

The SURPASS clinical trial program established tirzepatide as highly effective in metabolic research contexts. SURPASS-2 demonstrated superiority to semaglutide 1mg in both HbA1c reduction and body weight outcomes. SURMOUNT trials in adults with obesity showed mean body weight reductions of 15–22.5% at 72 weeks — outcomes that set a new benchmark in pharmacological weight management and drove significant research interest in the dual incretin mechanism.

The GIP receptor component contributes mechanistically to outcomes beyond GLP-1-mediated effects: GIP receptor activation in adipose tissue, bone, and brain introduces additional pathways for weight reduction that appear additive or synergistic. Research applications include comparative studies with GLP-1 monoagonists, investigation of the GIP receptor's metabolic role, and mechanistic work on the dual incretin system. The compound's structural complexity makes HPLC verification and cold-chain handling essential for reproducible research.